<DOC>
	<DOCNO>NCT00700440</DOCNO>
	<brief_summary>This open , multicenter phase Ⅱ clinical trial cetuximab ( C225 ) combine IMRT + concurrent chemotherapy cisplatin locoregionally advanced nasopharyngeal carcinoma .</brief_summary>
	<brief_title>Study Cetuximab Nasopharyngeal Carcinoma ( NPC ) With Chemoradiotherapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Informed consent form sign prior study entry Age 1869 year old Pathology approve nasopharyngeal carcinoma ( type WHO ⅡⅢ ) Stage Ⅲ , Ⅳa , Ⅳb accord UICC ( International Union Against Cancer ) 2002 6th edition criterion Primary tumor measurable KPS score ≥80 Expected life span ≥6 month Adequate bone marrow function : White Blood Cell≥4×109/L，Hemoglobin≥100g/L，Platelet≥100×109/L Adequate liver function : ALAT/ASAT＜1.5 × upper limit normal ( ULN ) , bilirubin ＜1.5×ULN Adequate renal function : Creatinine Clearance &lt; 1.5×ULN Evidence distant metastatic disease Surgical procedure primary tumor lymph node ( except diagnostic biopsy ) Previous radiotherapy primary tumor lymph node Previous exposure epidermal growth factortargeted therapy Prior chemotherapy immunotherapy primary tumor Other previous malignancy within 5 year , except nonmelanoma skin cancer preinvasive carcinoma cervix Any investigational agent prior 1st study medication Participation another clinical study within 30 day prior Inclusion study . Peripheral neuropathy &gt; grade 1 Known grade 3 4 allergic reaction study treatment History severe pulmonary cardiac disease Creatinine Clearance &lt; 30ml/min Know drug abuse / alcohol abuse Legal incapacity limit legal capacity Active systemic infection Medical psychiatric illness , investigator ' opinion , would permit subject complete fully completely understand risk potential complication study Concurrent chronic systemic immune therapy hormone therapy indicate study protocol Pregnancy ( confirm serum urine βHCG ) lactation period Severe intercurrent illness , e.g . uncontrolled hypertension , cardiac failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Radiotherapy</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>Drug Targeting</keyword>
	<keyword>loco-regionally advanced nasopharyngeal carcinoma</keyword>
	<keyword>Safety .</keyword>
	<keyword>efficacy</keyword>
</DOC>